Personalis, Inc. (PSNL)
NASDAQ: PSNL · Real-Time Price · USD
10.78
-0.36 (-3.23%)
At close: Jun 3, 2026, 4:00 PM EDT
10.74
-0.04 (-0.37%)
After-hours: Jun 3, 2026, 4:56 PM EDT
Personalis Revenue
Personalis had revenue of $15.47M in the quarter ending March 31, 2026, a decrease of -24.91%. This brings the company's revenue in the last twelve months to $64.52M, down -24.71% year-over-year. In the year 2025, Personalis had annual revenue of $69.65M, down -17.69%.
Revenue (ttm)
$64.52M
Revenue Growth
-24.71%
P/S Ratio
17.53
Revenue / Employee
$248,135
Employees
260
Market Cap
1.13B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 69.65M | -14.97M | -17.69% |
| Dec 31, 2024 | 84.61M | 11.13M | 15.15% |
| Dec 31, 2023 | 73.48M | 8.43M | 12.97% |
| Dec 31, 2022 | 65.05M | -20.45M | -23.92% |
| Dec 31, 2021 | 85.49M | 6.85M | 8.70% |
| Dec 31, 2020 | 78.65M | 13.44M | 20.61% |
| Dec 31, 2019 | 65.21M | 27.43M | 72.62% |
| Dec 31, 2018 | 37.77M | 28.38M | 302.15% |
| Dec 31, 2017 | 9.39M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Myriad Genetics | 829.00M |
| NeoGenomics | 745.97M |
| OPKO Health | 581.12M |
| Veracyte | 541.74M |
| GeneDx Holdings | 442.68M |
| CareDx | 412.82M |
| Castle Biosciences | 339.92M |
| Fulgent Genetics | 320.35M |
PSNL News
- 1 day ago - Personalis Highlights Early Colorectal Cancer Recurrence Detection and Ultrasensitive MRD Performance Across a Broad Set of Tumor Types at ASCO 2026 - Business Wire
- 8 days ago - Personalis to Highlight Breadth of NeXT Personal® Ultra-Sensitive ctDNA Data at ASCO 2026 Annual Meeting, Including Podium Presentation from TRACERx Consortium - Business Wire
- 14 days ago - Personalis secures fourth Medicare coverage decision for NeXT Personal - TheFly
- 14 days ago - Personalis Secures Fourth Medicare Coverage Decision for NeXT Personal®, Expanding Breast Cancer Coverage to Pre-Surgical Treatment Monitoring - Business Wire
- 20 days ago - Personalis to Participate in Upcoming Investor Events - Business Wire
- 21 days ago - Personalis announces that CMS program expanded coverage for NeXT - TheFly
- 21 days ago - Personalis Receives Medicare Coverage for NeXT Personal® for Immunotherapy Monitoring Across Late-stage Solid Tumors - Business Wire
- 22 days ago - Personalis Transcript: AGM 2026 - Transcripts